Johnson Memorial Cancer Center, Enfield, CT

Is Johnson Memorial Cancer Center registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Johnson Memorial Cancer Center hold a Connecticut pharmacy license?

No license with this exact name and city was found in the Connecticut Department of Consumer Protection file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed.

Has Johnson Memorial Cancer Center had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Nov 28, 2022), 1 state referral letter (Nov 28, 2022) and 1 FMD-145 letter (Nov 28, 2022) for Johnson Memorial Cancer Center. Connecticut board disciplinary actions: not checked, because the Connecticut Department of Consumer Protection data this index reads gives license status only and does not include disciplinary actions. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Johnson Memorial Cancer Center
Location
Enfield, CT
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Nov 28, 2022
FDA Data Dashboard inspections
3 inspections: 1 OAI, 2 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 10 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Johnson Memorial Cancer Center, a 503A facility, with 4 dated actions.

Document
Nov 28, 2022State referral letterState Referral Letter Issued 11/28/2022Not linked by FDA
Nov 28, 2022FMD-145 letterFMD-145 Letter Issued 11/28/2022Not linked by FDA
Nov 28, 2022Warning letter close-outWarning Letter Close Out Issued 11/28/2022Not linked by FDA
Oct 21, 2021Form 483483 Issued 10/21/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Johnson Memorial Cancer Center, Enfield, CT (FEI number 3010955218), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Oct 21, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30109552181155105
Oct 19, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30109552181070172
Aug 5, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3010955218890813

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 10 numbered observations in all, across 2 inspections ending Oct 19, 2018 to Oct 21, 2021. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Sep 20, 2021 to Oct 21, 2021: 4 observations

Firm on the cover
Johnson Memorial Cancer Center, 142 Hazard Ave, Enfield, CT 06082-4520
FEI number
3010955218
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
One Montvale Avenue Stoneham, MA 02180
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced hazardous drugs without providing adequate cleaning of work surfaces to prevent cross-contamination.

Specifically, poor cleaning practices were observed during the production of hazardous sterile drug products in the firm's ISO 5 Biological Safety Cabinet (BSC) located in the IOS 7 <Redacted B4> room.

1) On 09/21/2021, a Pharmacy Technician was observed producing Cisplatin Order # <Redacted B4>, Pembrolizurnab Order # <Redacted B4>, and Etoposide Order# <Redacted B4> in the ISO 5 BSC. The technician failed to clean the internal (ISO 5 side) of the BSC view screen between producing the sterile drug products in the BSC.

2) On 09/22/2021, a Pharmacy Technician was observed cleaning the ISO 5 BSC and then producing Bortezomib Order # <Redacted B4> in the ISO 5 BSC.

0 The technician failed to clean the internal (ISO 5 side) of the BSC view screen immediately prior to performing sterile production activities. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Materials or supplies were not disinfected prior to entering the aseptic processing areas.

Specifically, on 09/22/2021, a Pharmacy Technician was observed cleaning the ISO 5 BSC and then producing Bortezomib Order # <Redacted B4> in the ISO 5 BSC. During the production of Bortezomib, the technician failed to clean the septum of each of the two vials of sterile drug product with Sterile <Redacted B4> immediately prior to performing sterile production activities.

Observation 3

You had inadequate HEP A filter coverage and airflow over the area to which sterile product was exposed.

Specifically, you conducted air pattern analyses (smoke studies) on 08/21/2020, 02/22/2021 and 08/19/2021 for the ISO 5 Biological Safety Cabinet (BSC) used to produce chemotherapeutic drug products and the ISO 5 Laminar Flow Hood (LFH) used to produce non-hazardous drug products. The smoke studies performed were deficient:

0 The 08/2020 studies for the BSC and LFH, and the 08/2021 study for the LFH did not include the transfer of all starting components and materials into the ISO 5 classified areas.

0 The 8/2020 studies for the BSC and LFH, the 02/2021 studies for the BSC and LFH, and the 08/2021 studies for the BSC and LFH failed to include all manipulations and transfers performed by the operator during production.

0 In addition, the smokes studies performed in the BSC failed to simulate the most complex product produced, which was identified as Leucovorin.

This is a repeat of Observation # 6 from the 2018 inspection.

Observation 4

Disinfecting agents used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically, you use non-sterile disinfecting agent <Redacted B4> to disinfect the interior surfaces of your ISO 5 Biological Safety Cabinet (BSC) and the interior surfaces of your ISO 5 Laminar Flow Hood (LFH).

Inspection Oct 1, 2018 to Oct 19, 2018: 6 observations

Firm on the cover
Johnson Memorial Cancer Center, 142 Hazard Ave, Enfield, CT 06082-4 520
Establishment type on the cover
Producer of Sterile Drug Products
FDA district office on the cover
ONE MONTVALE AVENUE STONEHAM, M A 0218 0
Matched to this page by
firm name, city and state on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in the ISO 5 classified aseptic processing area during aseptic production.

Date Reported

Location

Recovery Type

Total number of colonies

Microbiological Identification

Biological Safety Cabinet aso 5)

Air

Penicillium spp. 1 (mold)

Laminar Air Flow Hood (ISO 5)

Air

C,yptococcus spp.2 (mold)

Laminar Air Flow Hood (ISO 5)

Air

2 Bacillus cereus

Laminar Air Flow Hood (ISO 5)

Surface 3

1 Bacillus cereus, 2 Unidentified Gram+ Sporeforming Rods

1 The firm's contract laboratory identified these genera of fungi are known to have strains which may produce mycotoxins under the proper conditions.

2 The firm's contract laboratory identified this microorganism as potentially highly pathogenic for immunocompromised patients.

Observation 2

You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.

Date Reported

Location

Recovery Type

Total number of colonies

Microbiological Identification

Anteroom (ISO 7)

Air

Aspergillus fumigatus1 (mold)

Non-Hazardous Drug Buffer Room (ISO 7)

Air

Cladosporium spp.1 (mold)

Non-Hazardous Drug Buffer Room (ISO 7)

Air

Epicoccum spp. (mold)

Non-Hazardous Drug Buffer Room (ISO 7)

Surface

4 Bacillus cereus, 2 Unidentified Gram+ Sporefonning Rods

Anteroom (ISO 7)

Surface

1Bacillus cereus, 1Unidentified Gram+ Sooreformi.ng Rods

Anteroom Sink (ISO 7)

Surface

3 Bacillus cereus, 1Unidentified Gram+ Sporefonning Rods

1 The firm's contract laboratory identified these genera of fungi are known to have strains which may produce mycotoxins under the proper conditions.

The following actionable environmental excursions were reported recovered in the sunounding and supporting ISO 7 classified areas during the current inspection.

Date Reported

Location

Recovery Type

Total number of colonies

Microbiological Identification ...

Read the full 483 (PDF on fda.gov)

Observation 3

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically ,

The firm failed to maintain proper room classification and environmental control of supporting areas in which ISO 5 classified aseptic processing equipment is located and sterile production occurs. The firm's air handling unit (AHU) was offline from 05/15/18 to 05/18/18, 6/01/18 to 6/04/18, and for approximately 10 hours on 06/06/18. This resulted in elevated temperatures and relative humidity levels, and loss of differential pressures for smrnunding buffer and ante areas, for each of the offline time periods. Production activities were not always suspended during these offline timeframes. For example,on 6/01/18, the firm continued to produce <Redacted B4> chemotherapeutic dmg products for injection, inside the ISO 5 Biological Safety Cabinet, even though there was a lack of adequate HEP A filtered airflow to the surrounding buffer and ante areas to maintain an adequate room cleanliness classification.

Observation 4

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically, The firm's cleaning of the ISO 5 Biological Safety Cabinet and ISO 5 Laminar Flow Hood are inadequate for the following reasons:

0 The firm routinely utilizes non-sterile wipes <Redacted B4> to administer sterile <Redacted B4> (sporicidal disinfectant) and sterile <Redacted B4> to all interior surfaces of the ISO 5 hoods. In addition. the firm utilizes the non-sterile wipes to dry residual cleaning agents <Redacted B4> from the interior of the ISO 5 hoods. The firm has performed no risk assessments related to the use of non-sterile wipes in the ISO 5 classified areas where aseptic processing occurs.

0 Firm personnel were observed cleaning the interior of the ISO 5 classified areas with their head and upper torso within the hood. The operator's gowning was observed coming into contact with the interior surfaces of the hood. The firm has performed no risk assessments related to the aforementioned cleaning activities.

0 The firm 's contact time for the use of the sporicidal disinfectant <Redacted B4> hiffered from the manufacturer's recommendations. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Personnel moved rapidly in the vicinity of open sterile units and instruments, which disrupted the airflow and increased the risk of bringing lesser quality air into the ISO 5 classified aseptic processing area.

Specifically, poor aseptic practice was observed during the production of sterile drug products while working within ISO 5 classified aseptic processing areas.

1) On 10/1/18, an operator was observed producing <Redacted B4> for injection in the firm's ISO 5 Laminar Flow Hood (LFH). The LFH is located in an ISO 7 Buffer room.

o The operator's hands exited and entered the LFH several times during operations to gather supplies and continue production. The operator did not sanitize their hands upon each entry to LFH.

o The operator failed to keep all production activities at least 6 inches inside the LFH.

o The operator's movements inside the LFH were quick, abrupt and had potential to disturb ISO 5 airflow.

o The operator was observed wearing eye makeup.

2) On 10/2/18, an operator was observed producing <Redacted B4> and <Redacted B4> for injection in the firm's ISO 5 Laminar Flow Hood (LFH). The LFH is located in an ISO 7 Buffer room. ...

Read the full 483 (PDF on fda.gov)

Observation 6

You had inadequate HEP A filter coverage and airflow over the area to which sterile product was exposed.

Specifically, The firm's air pattern analysis and media fills are deficient for the following reasons:

1) The firm conducted an air pattern analysis (smoke study) on 02/22/18 and 08/15/18 for the ISO 5 Biological Safety Cabinet (BSC) utilized for the production of chemotherapeutic drug products and the ISO 5 Laminar Flow Hood (LFH) utilized for the production of non-hazardous drug products. The aforementioned smoke studies were inadequate as the studies did not include the transfer of staying components and materials into the ISO 5 classified areas. In addition, the firm's smoke studies for the BSC failed to simulate the most complex product to produce, which was identified as <Redacted B4>

Biological Safety Cabinet (BSC) utilized for the production ofchemotherapeutic diug products and the ISO 5 Laminar Flow Hood (LFH) utilized for the production ofnon-hazardous diug products. The aforementioned smoke studies were inadequate as the studies did not include the transfer of staiiing components and materials into the ISO 5 classified ai·eas. ...

Read the full 483 (PDF on fda.gov)

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the Connecticut Department of Consumer Protection file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The dataset gives each license’s status and status reason in the department’s words but lists no disciplinary actions, so Connecticut board actions are not checked.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.